1.Lode H, Hoffken G, Boeckk M, Deppermann N, Borner K, Koeppe P. Quinolone pharmacokinetics and metabolism. J Antimicrob Chemother. 1990;26 Suppl B:41–9.
2.Mant TG. Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing. Am J Med. 1992;92(4a):26s–32s.
3.Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ open. 2015;5(11):e010077.
4.Hsu SC, Chang SS, Lee MG, Lee SH, Tsai YW, Lin SC, et al. Risk of gastrointestinal perforation in patients taking oral fluoroquinolone therapy: An analysis of nationally representative cohort. PloS one. 2017;12(9):e0183813.
5.Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. Jama. 2012;307(13):1414–9.
6.Stephenson AL, Wu W, Cortes D, Rochon PA. Tendon Injury and Fluoroquinolone Use: A Systematic Review. Drug Saf. 2013;36(9):709–21.
7.Pasternak B, Inghammar M, Svanstrom H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. Bmj. 2018;360:k678.
8.Sendzik J, Shakibaei M, Schafer-Korting M, Stahlmann R. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase–3 in cultured human tendon cells. Toxicology. 2005;212(1):24–36.
9.Sykes EM, Jr. Colon perforation in Ehlers-Danlos syndrome. Report of two cases and review of the literature. Am J Surg. 1984;147(3):410–3.
10.Germain DP. Clinical and genetic features of vascular Ehlers-Danlos syndrome. Ann Vasc Surg. 2002;16(3):391–7.
11.Administration. USFaD. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients [Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics.
12.Administration. USFaD. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects [Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics.
13.Jackson MA, Schutze GE. The Use of Systemic and Topical Fluoroquinolones. Pediatrics. 2016;138(5).
14.Pediatric Infectious Diseases Society of Taiwan CHRC, National Health Research Institutes. Recommendations for the Use of New Quinolone Antibiotics in Children.
15.Patel K, Goldman JL. Safety Concerns Surrounding Quinolone Use in Children. Journal of clinical pharmacology. 2016;56(9):1060–75.
16.Yi FH. The Prescribing Pattern of Fluoroquinolone in Pediatric Patients in Taiwan. Tainan City: National Cheng Kung University; 2013.
17.Pediatric Infectious Diseases Society of Taiwan CHRC, National Health Research Institutes. Recommendations for the Diagnosis and Management of Acute Otitis Media in Children [Available from: http://www.pids.org.tw/index.php?route = news/news_detail&news_id = 96.
18.Lee CC, Lee MT, Chen YS, Lee SH, Chen YS, Chen SC, et al. Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. JAMA Intern Med. 2015;175(11):1839–47.
19.Dixit A, Karandikar MV, Jones S, Nakamura MM. Safety and Tolerability of Moxifloxacin in Children. J Pediatric Infect Dis Soc. 2018;7(3):e92-e101.
20.Choi S-H, Kim EY, Kim Y-J. Systemic use of fluoroquinolone in children. Korean journal of pediatrics. 2013;56(5):196–201.
21.Lin L-Y, Warren-Gash C, Smeeth L, Chen P-C. Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol Health. 2018;40:e2018062-e.
22.Hsieh C-Y, Su C-C, Shao S-C, Sung S-F, Lin S-J, Kao Yang Y-H, et al. Taiwan’s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349–58.
23.Administration. USFaD. FDA updates warnings for fluoroquinolone antibiotics [Available from: https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics.
24.Wu CT, Lee HY, Chen CL, Tuan PL, Chiu CH. High prevalence and antimicrobial resistance of urinary tract infection isolates in febrile young children without localizing signs in Taiwan. J Microbiol Immunol Infect. 2016;49(2):243–8.
25.Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emergency Medicine Journal. 2003;20(1):54–60.
26.Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg. 2010;126(6):2234–42.
27.Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89–92.
28.Sidloff D, Choke E, Stather P, Bown M, Thompson J, Sayers R. Mortality from thoracic aortic diseases and associations with cardiovascular risk factors. Circulation. 2014;130(25):2287–94.
29.Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. The Lancet. 2010;376(9735):124–36.
30.Marso SP, Hiatt WR. Peripheral Arterial Disease in Patients With Diabetes. Journal of the American College of Cardiology. 2006;47(5):921–9.
31.Kardas P. Noncompliance in Current Antibiotic Practice. Infectious Diseases in Clinical Practice. 2006;14(4):S11-S4.
32.Chen C, Chen YM, Hwang KL, Lin SJ, Yang CC, Tsay RW, et al. Behavior, attitudes and knowledge about antibiotic usage among residents of Changhua, Taiwan. J Microbiol Immunol Infect. 2005;38(1):53–9.
33.Mazzali C, Duca P. Use of administrative data in healthcare research. Intern Emerg Med. 2015;10(4):517–24.